What are Johnson & Johnson's main business segments, and how are they structured?

Johnson & Johnson operates through three main segments: Consumer (baby care, skin care, oral care, wound care, women's health, nutritional products, and over-the-counter pharmaceuticals), Pharmaceutical (prescription drugs for various therapeutic areas like immunology, oncology, and neuroscience), and Medical Devices and Diagnostics (products for cardiovascular disease, orthopaedics, diabetes care, surgery, and contact lenses). The company utilizes a decentralized management structure with over 275 operating companies globally, coordinating through an Executive Committee.

What is the company's R&D investment strategy, and what are the key R&D expenditures?

Johnson & Johnson demonstrates a strong commitment to research and development, viewing it as significant to its business. In fiscal year 2012, R&D expenditures amounted to $7.7 billion. These investments are focused on discovering, testing, and developing new products, as well as improving existing ones, across all business segments, with major research facilities located globally.

How is the company addressing regulatory challenges and legal proceedings?

The company operates in a heavily regulated industry and acknowledges the increasing stringency of global regulations, including the U.S. Patient Protection and Affordable Care Act. It also mentions a consent decree with the FDA affecting certain manufacturing operations for McNeil Consumer Healthcare, which is expected to impact production volumes through most of 2013. The company believes it complies with environmental laws and is addressing specific allegations without expecting significant adverse impact.

What is the impact of patent expirations on Johnson & Johnson's business?

The expiration of market exclusivity for key products presents a challenge. For example, LEVAQUIN® lost market exclusivity in the U.S. in 2011, resulting in a significant sales decline of approximately 94% in 2012 due to generic competition. The company's strong patent portfolio for products like REMICADE® is considered material to its ongoing operations.

JNJ 10-K Filed Feb 22, 2013

Summary

Johnson & Johnson (JNJ) filed its 2012 10-K report on February 22, 2013, detailing its operations across three primary segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. The company operates a decentralized management structure with over 275 subsidiaries globally, emphasizing human health and well-being. A significant aspect highlighted is the company's commitment to research and development, with substantial investments totaling $7.7 billion in 2012, aimed at delivering innovative products across its diverse portfolio. Investors should note the company's robust patent and trademark protection, crucial for its key products like REMICADE®. The report also addresses the impact of patent expirations, such as LEVAQUIN® losing market exclusivity in the U.S. in 2011, leading to a substantial sales decline in 2012. Furthermore, the company acknowledges the evolving regulatory landscape, particularly concerning healthcare costs and the Patient Protection and Affordable Care Act in the U.S., alongside ongoing legal proceedings, including a consent decree with the FDA impacting certain manufacturing operations.

Key Highlights

1Johnson & Johnson operates through three main business segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics, serving a broad range of healthcare needs globally.
2The company maintains a decentralized management structure with over 275 operating companies in 60 countries, ensuring local market responsiveness.
3Significant investment in Research and Development (R&D) continues, with $7.7 billion spent in fiscal year 2012, demonstrating a commitment to innovation and product pipeline development.
4Key pharmaceutical products include REMICADE®, STELARA®, ZYTIGA®, and XARELTO®, with REMICADE® representing approximately 9.1% of total revenues in 2012.
5The company is actively managing the impact of patent expirations, such as LEVAQUIN®, which experienced a 94% sales decline in the U.S. in 2012 due to generic competition.
6Manufacturing operations, particularly for McNeil Consumer Healthcare, are subject to a consent decree with the FDA, impacting production volumes and requiring simplified product portfolios from specific facilities through most of 2013.
7The company emphasizes strong patent and trademark protection as critical to its business operations and competitive position.

JOHNSON & JOHNSON Annual Report, Year Ended Dec 30, 2012

Summary

Key Highlights

Frequently Asked Questions